Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q3 2024 Earnings Presentation
17 slides from Bactiguard Holding Ab's earnings presentation, Oct 24, 2024
Slide 1: Interim report Q3 2024 presentation
Interim report Q3 2024 presentation Thursday 24 October 2024 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Q3 Summary
Q3 SUMMARY Delivers positive EBITDA and initiates review of 2028 financial targets due to previously announced agreement termination
Slide 3: Q3 2024 key figures and highlights
Q3 2024 key figures and highlights Bactiguard turns profitable on EBITDA level in third quarter Key figures Q3 2024 (Q3 2023) Highlights from Q3 • Profitability on EBITDA level Revenues 73.9 (49.5) MSEK • Solid growth in BD main driver of EBITDA • Strong third quarter for Wound Management EBITDA 9.9
Slide 4: Advanced infection prevention technology
Advanced infection prevention technology Reduces microbial adhesion and biofilm formation on medical devices • Biocompatible, safe and proven – reduces the risk of medical device related infections • Ultra-thin noble metal coating technology; gold, silver and palladium • In contact with fluids, the
Slide 5: Critical global healthcare trends driving market needs
Critical global healthcare trends driving market needs The issues The market opportunity (USD 80bn) • Antimicrobial resistance one of the top global public health threats facing humanity – associated with the Orthopedics 40 death of close to 5 million people globally in 2019 • 1 in 10 patients world
Slide 6: Effective license focused strategy and business model
Effective license focused strategy and business model Increased interest in our infection prevention technology from MedTech companies R&D License Medical Wound Management partnerships Regulatory portfolio Focus: advance current Focus: deliver competencies Focus: grow profitably and develop future t
Slide 7: Business model and partner journey
Business model and partner journey Three types of revenues – partners generating exclusivity and license revenues are communicated 7
Slide 8: Solid BD growth drives EBITDA for Q3
Solid BD growth drives EBITDA for Q3 Global partnership approach – BD’s success is Bactiguard’s success • Revenues from BD collaboration main driver of EBITDA • Close collaboration on expansion of Bactiguard-coated Foley catheters into both existing and new markets • Engagement across the entire val
Slide 9: Zimmer Biomet trauma agreement remains in effect
Zimmer Biomet trauma agreement remains in effect Infection rates and medical need significantly higher in trauma segment • Termination of the multiple orthopedic product segment agreement announced early October • Ongoing trauma collaboration also includes work with regulatory processes in Europe an
Slide 10: Wound Management by Bactiguard
Wound Management by Bactiguard Preventing infections by offering effective, biocompatible solutions to improve wound healing • Continued path of profitable growth during the third quarter • Published results of randomized study in peritoneal and wound lavage* – reduced overall surgical-site infectio
Slide 11: Total revenue Q3 2024
Total revenue Q3 2024 Solid growth in license revenues, notably from BD partnership • Total license revenue amounted to 47.5 (20.8) MSEK • Revenues from BD amounted to 33.3 (9.2) MSEK • Revenues from Zimmer Biomet Jul-Sep Jan-Sep Full year RTM amounted to 10.7 (11.6) MSEK MSEK 2024 2023 2024 2023 20
Slide 12: Net sales grew 48% in Q3 and 23% YTD
Net sales grew 48% in Q3 and 23% YTD, driven by solid growth in license revenues Net sales distribution SEK million BIP portfolio Wound Management portfolio License revenues Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 235 +23% 23 202 179 31 59 13 145 45 54 20 +48% 40 67 153 45 2 120
Slide 13: EBITDA grew to 9.9 MSEK in Q3 and to 9.6 MSEK YTD
EBITDA grew to 9.9 MSEK in Q3 and to 9.6 MSEK YTD EBITDA SEK million Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM +19.4 +81.4 9.9 9.6 5.3 -9.5 -71.8 -76.1 2023 2024 2023 2024 2023 2023/24 13 Source: Bactiguard Holding AB, Interim report Q3 2024, p. 17
Slide 14: Total operating expenses and cash flow Q3 2024
Total operating expenses and cash flow Q3 2024 On track to deliver cost savings exceeding 25 MSEK on a yearly basis following the transformation Operating expenses Cash flow • Costs for raw materials and consumables • Cash flow from operating activities amounted amounted to -6.9 (-10.5) MSEK, a decr
Slide 15: Our priorities ahead
Our priorities ahead – focus is still in focus Vision: become the global standard of care for preventing medical device related infections • Advance current partnerships – with BD, Zimmer Biomet and Well Lead • New partnerships in strategic therapeutic areas – convert early-stage projects into exclu
Slide 16: Q&A
Q&A to champion a healthier world by preventing infections
Slide 17: Questions & Answers
Questions & Answers End of Q3 2024 presentation Christine Lind Patrick Bach CEO CFO